OPTN OptiNose

Optinose Announces Reporting Date for Fourth Quarter and Full Year 2024 Financial Results

Optinose Announces Reporting Date for Fourth Quarter and Full Year 2024 Financial Results

Conference Call and Webcast to be held March 20, 2025, at 8:00 a.m. Eastern Time

YARDLEY, Pa., March 11, 2025 (GLOBE NEWSWIRE) -- (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced the Company will report financial results for the fourth quarter and full year of 2024 and corporate updates, before market open, on Thursday, March 20, 2025.

Company to Host Conference Call

Members of the Company’s leadership team will host a conference call to discuss financial results and corporate updates. The call is scheduled to start at 8:00 a.m. Eastern Time on Thursday, March 20, 2025.

Participants may access the conference call live via webcast by visiting the Investors section of Optinose’s website at . To participate via telephone, please register in advance at . Upon registration, all telephone participants will receive a confirmation email detailing how to join the conference call, including the dial-in number and a personal PIN that can be used to access the call. In addition, a replay of the webcast will be available on the Company website for 60 days following the event.

About Optinose

Optinose is a specialty pharmaceutical company focused on serving the needs of patients cared for by ear, nose and throat (ENT) and allergy specialists. To learn more, please visit  or follow us on and .

Optinose Investor Contact

Jonathan Neely



267.521.0531



EN
11/03/2025

Underlying

OPTNOptiNose

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on OptiNose

 PRESS RELEASE
Free
OPTN OPTINOSE

Optinose Reports Fourth Quarter and Full Year 2024 Financial Results a...

Optinose Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Operational Highlights Company reports fourth quarter and full year 2024 XHANCE net revenue of $22.4 million and $78.2 million, increases of 13% and 10% compared to prior year periods Company reports 23% prescription growth from third quarter 2024 to fourth quarter 2024 YARDLEY, Pa., March 26, 2025 (GLOBE NEWSWIRE) --  (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today reported financial results for the quarter and year ended Dece...

March 26, 2025 1 EN
 PRESS RELEASE
Free
OPTN OPTINOSE

Optinose Cancels Fourth Quarter and Full Year 2024 Earnings Call

Optinose Cancels Fourth Quarter and Full Year 2024 Earnings Call YARDLEY, Pa., March 19, 2025 (GLOBE NEWSWIRE) -- (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced the cancellation of its earnings conference call for the quarter and full year ended December 31, 2024 that had originally been scheduled for March 20, 2025 at 8:00 a.m. Eastern Time. The call is being cancelled due to the announcement earlier today that Optinose has entered into a definitive agreement to be acquired by Paratek Pharmaceut...

March 20, 2025 1 EN
 PRESS RELEASE
Free
OPTN OPTINOSE

Optinose Announces Reporting Date for Fourth Quarter and Full Year 202...

Optinose Announces Reporting Date for Fourth Quarter and Full Year 2024 Financial Results Conference Call and Webcast to be held March 20, 2025, at 8:00 a.m. Eastern Time YARDLEY, Pa., March 11, 2025 (GLOBE NEWSWIRE) -- (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced the Company will report financial results for the fourth quarter and full year of 2024 and corporate updates, before market open, on Thursday, March 20, 2025. Company to Host Conference CallMembers of the Company’s leadership team w...

March 11, 2025 1 EN
 PRESS RELEASE
Free
OPTN OPTINOSE

Optinose Announces Preliminary Unaudited Fourth Quarter 2024 XHANCE Ne...

Optinose Announces Preliminary Unaudited Fourth Quarter 2024 XHANCE Net Revenue of $22.4 Million Preliminary XHANCE prescription growth rate from third quarter to fourth quarter 2024 estimated to be approximately 20% YARDLEY, Pa., Jan. 15, 2025 (GLOBE NEWSWIRE) --  (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced preliminary unaudited XHANCE® (fluticasone propionate) net product revenue of $22.4 million for the three months ended December 31, 2024. “Our preliminary unaudited fourth quarter n...

January 15, 2025 1 EN
 PRESS RELEASE
Free
OPTN OPTINOSE

Optinose Announces 1-for-15 Reverse Stock Split

Optinose Announces 1-for-15 Reverse Stock Split YARDLEY, Pa., Dec. 26, 2024 (GLOBE NEWSWIRE) -- Optinose, Inc. (NASDAQ: OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced that it will effect a 1-for-15 reverse stock split at 5:00 p.m. Eastern Standard Time, on December 30, 2024. Beginning with the opening of trading on December 31, 2024, Optinose’s common stock will trade on the Nasdaq Global Select Market (“Nasdaq”) on a split-adjusted basis under a new CUSIP number 68404V209 and Optinose’s existing trading s...

December 26, 2024 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch